GSA Capital Partners LLP Sells 2,557 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

GSA Capital Partners LLP decreased its position in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 1.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 165,575 shares of the company’s stock after selling 2,557 shares during the period. GSA Capital Partners LLP’s holdings in GoodRx were worth $1,149,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. American Century Companies Inc. bought a new position in GoodRx in the 2nd quarter valued at approximately $18,183,000. Rubric Capital Management LP lifted its holdings in shares of GoodRx by 76.5% during the second quarter. Rubric Capital Management LP now owns 3,736,802 shares of the company’s stock valued at $29,147,000 after purchasing an additional 1,619,748 shares in the last quarter. Millennium Management LLC boosted its position in shares of GoodRx by 36.5% during the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after buying an additional 1,102,758 shares during the last quarter. Raymond James & Associates increased its holdings in GoodRx by 212.6% in the 3rd quarter. Raymond James & Associates now owns 394,006 shares of the company’s stock worth $2,734,000 after buying an additional 267,951 shares in the last quarter. Finally, Picton Mahoney Asset Management raised its position in GoodRx by 24.3% in the 2nd quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock worth $4,736,000 after buying an additional 118,703 shares during the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GDRX has been the subject of a number of research analyst reports. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a research note on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. UBS Group dropped their price target on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Barclays reduced their price objective on GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday. Finally, Citigroup dropped their target price on GoodRx from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, GoodRx has an average rating of “Moderate Buy” and an average price target of $8.86.

Insiders Place Their Bets

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.17% of the stock is currently owned by corporate insiders.

GoodRx Price Performance

Shares of GoodRx stock opened at $4.56 on Friday. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -155.33, a PEG ratio of 3.24 and a beta of 1.39. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock’s 50-day simple moving average is $6.69 and its 200-day simple moving average is $7.46. GoodRx Holdings, Inc. has a 52 week low of $4.55 and a 52 week high of $9.26.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.